My Myeloma and CAR T Cell Experience, by Daniel Riebow
Clinical Trial: Natural Killer Cells Clinical Trial in Phase I for Relapsed and Refractory Multiple Myeloma Patients
Staying On Myeloma Maintenance Therapy - How Long and Which Drug(s)?
Experts' Picks: The Best Of ASH (The American Society Of Hematology) in Summary
How Immunomodulators Work in Multiple Myeloma
C-Reactive Protein (Inflammation) Levels Before Transplant Can Indicate Overall Myeloma Survival
FDA Approves Denosumab Bone Strengthener for Myeloma Patients
Looking to 2018 in Myeloma Care with Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center
Where are we headed in 2018? Dr. Robert Z. Orlowski of the MD Anderson Cancer Center joins us to share the latest.
Janssen Oncology Jumps Into Myeloma BCMA CAR T Field in Collaboration With Chinese Firm Legend Bio
ASH 2017: Experts' Picks - Daratumumab with Revlimid, Velcade and Dex
ASH 2017: Myeloma, Bloodclots and Aspirin
ASH 2017: Second Line Therapy to Deepen Responses Before Transplant Provides Worse Outcomes Than Just Going to Transplant Immediately
ASH 2017: Myeloma Patients Need a Flu Shot Booster!
Adaptive's Next Generation Sequencing Tool Used in Myeloma Clinical Trial to Track Minimal Residual Disease Status
Mayo Clinic Shows Myeloma Expertise Matters for Long Term Outcomes
Clinical Trial: Comparing Oral Myeloma Medications (ixazomib/dex vs. pomalidomide/dex)
Understanding the Myeloma Stem Cell Transplant Process
ASH 2017: Quick ‘Do-It-Yourself’ M-Spike Calculation, the Gamma Gap
Guidance for use of Pomalidomide in Relapsed/Refractory Myeloma Patients on Dialysis
New Bone Strengthener Shows Greater Anti-Myeloma Effect and Convenience
Jackson Round Table - November 11, 2017
Clinical Trial: KITE Pharma's CAR T Cell Trial for Relapsed/Refractory Myeloma
Myeloma Co-Pay Assistance Plans Faltering is a Crisis for Some Patients
Your Myeloma Antibody Type May Affect How You Respond to Darzalex
